Want to see HK:2005 full AI Analyst Report?
2005 Stock Chart & Stats
HK$2.68
HK$0.03(1.26%)
At close: 4:00 PM EDT
HK$2.68
HK$0.03(1.26%)
Day’s Range― - ―
52-Week RangeHK$2.01 - HK$3.18
Previous CloseN/A
Volume1.37M
Average Volume (3M)4.20M
Market Cap
HK$7.82B
Enterprise ValueHK$8.55B
Total Cash (Recent Filing)HK$1.97B
Total Debt (Recent Filing)HK$4.05B
Price to Earnings (P/E)15.2
Beta0.69
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.2%
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,951,113,300
10 Day Avg. Volume4,056,030
30 Day Avg. Volume4,199,349
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)1.14
Price to Sales (P/S)1.99
P/FCF Ratio27.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$4.02Price Target Upside49.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable LeverageModerate and relatively stable leverage reduces balance-sheet strain and preserves financial flexibility. The large equity base provides support through weaker periods, while controlled debt exposure should leave the company better positioned to fund operations and pursue growth over the next several quarters.
Asset Base GrowthSustained asset growth indicates that the company has expanded its operating and financial base over time. This provides a foundation for future revenue generation and demonstrates accumulated scale, even though the latest year showed weaker returns and profitability than prior periods.
Positive Cash GenerationThe return to positive and improved operating and free cash flow strengthens internal funding capacity after the prior year's weak result. Continued cash generation can support investment, balance-sheet resilience, and shareholder returns without relying as heavily on external financing.
Bears Say
Revenue ContractionA material revenue decline indicates weaker business activity and reduces the scale from which future earnings can grow. Unless revenue stabilizes, the contraction may limit operating leverage, constrain reinvestment capacity, and keep pressure on profitability over the coming quarters.
Margin CompressionThe sharp step-down in gross, operating, and net margins shows that earnings quality weakened alongside revenue. Lower margins reduce the profit captured from each unit of sales and make future earnings more sensitive to further changes in demand or operating performance.
Lower Return On EquityThe decline in return on equity signals that the company generated substantially less profit from its shareholder capital in the latest year. If sustained, weaker capital efficiency could reduce compounding potential and make the expanded asset base less productive.
SSY Group News
2005 FAQ
What was SSY Group Limited’s price range in the past 12 months?
SSY Group Limited lowest stock price was HK$2.01 and its highest was HK$3.18 in the past 12 months.
What is SSY Group Limited’s market cap?
SSY Group Limited’s market cap is HK$7.82B.
When is SSY Group Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were SSY Group Limited’s earnings last quarter?
Currently, no data Available
Is SSY Group Limited overvalued?
According to Wall Street analysts SSY Group Limited’s price is currently Undervalued.
Does SSY Group Limited pay dividends?
SSY Group Limited pays a Semiannually dividend of HK$0.055 which represents an annual dividend yield of 3.2%. See more information on SSY Group Limited dividends here
What is SSY Group Limited’s EPS estimate?
SSY Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SSY Group Limited have?
SSY Group Limited has 2,951,113,300 shares outstanding.
What happened to SSY Group Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of SSY Group Limited?
Currently, no hedge funds are holding shares in HK:2005
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SSY Group Limited
SSY Group Limited, an investment holding company, researches, develops, manufactures, trades in, and sells various pharmaceutical products to hospitals and distributors in the People’s Republic of China and internationally. The company offers intravenous infusion solutions, including non-PVC and upright soft bag, PP plastic bottle, and glass bottle infusion solutions, as well as ampoule injections. It also provides small volume injections, oral preparations, Chinese medicine preparations, and biological preparations, as well as bulk pharmaceutical products and medical materials. In addition, the company is involved in the research, development, and consulting of pharmaceutical technology; provision of logistics services for pharmaceutical products; food, beverages, and catering businesses; and production and sale of methylamine. It sells its products under the Shimen brand name. The company was formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd. and changed its name to SSY Group Limited in May 2015. The company was founded in 1999 and is headquartered in Wan Chai, Hong Kong.
2005 Stock 12 Month Forecast
Average Price Target
HK$4.02
▲(49.88% Upside)
Technical Analysis
China Traditional Chinese Medicine Holdings Co
―
Wai Yuen Tong Medicine Holdings Limited
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Pak Fah Yeow International Limited
―
China Shineway Pharmaceutical Group Limited
―








